

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Bhatla, Teena

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Associate Professor of Pediatrics

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
SMS Medical College	MD	12/2000	Medicine
SMS Medical College, Jaipur	Resident	06/2004	Pediatrics
Maimonides Medical Center, Brooklyn, NY	Resident	06/2008	Pediatrics
New York University School of Medicine, New York, NY	Fellow	11/2011	Pediatric Hematology Oncology

**A. Personal Statement**

I am an Attending Physician (affiliations with St. Barnabas Medical Center and JFK Medical Center), Associate Professor of Pediatrics at Rutgers New Jersey Medical School and Director of the Division of Pediatric Hematology-Oncology at Newark Beth Israel Medical Center. I completed my undergraduate training in India and earned my medical degree at SMS Medical College (Jaipur, India) where I graduated with medical school honors in Anatomy, pathology and pediatrics. Following my internal medicine internship, I accomplished residency training in pediatrics at Maimonides Medical Center, where one year was waived by the American Academy of Pediatrics based on my previous experience in residency training in pediatrics in India. I have considerable experience in pediatric hematologic malignancies including Leukemia and Lymphoma. I serve in various clinical supervisory and training roles teaching residents, clinical and resident fellows (post-docs). I am committed to ensuring patients receive the best treatments delivered in the best ways, and to use better research-driven strategies to protect and preserve the health of survivors.

**B. Positions, Scientific Appointments and Honors****Positions and Scientific Appointments**

2019 -	Associate Professor of Pediatrics, Rutgers New Jersey Medical School
2019 -	Attending Physician, JFK Medical Center
2018 -	Director, Division of Pediatric Hematology-Oncology, Newark Beth Israel Medical Center
2018 -	Attending Physician, St. Barnabas Medical Center
2018 -	Member, Protocol committee COG ADVL1823 study
2018 -	Member, Protocol committee COG AALL1331 study
2018 -	Institutional PI, Children's Oncology Group
2018 -	Committee member, COG ALL
2018 -	Steering Committee member, ALL2005 Janssen study
2018 -	Task force member, COG T-ALL
2018 -	Institutional Principal Investigator, Children's Oncology Group
2016 -	Member, Protocol committee COG ADVL1521 study
2016 - 2019	Director, Pediatric Hematologic Malignancies Program, New York University School of Medicine
2014 - 2017	Assistant Professor of Pediatrics, Division of Pediatric Hematology-Oncology, New York University School of Medicine
2012 -	Member, Children's Oncology Group

2012 - 2017 Attending Physician, Bellevue Medical Center  
2012 - 2017 Attending Physician, Woodhull Medical Center  
2011 - Member, American Society of Pediatric Hematology-oncology  
2011 - 2014 Instructor, Division of Pediatric Hematology-Oncology, New York University School of Medicine  
2010 - Member, American Society of Hematology  
2005 - Member, American Academy of Pediatrics  
2004 - 2005 Senior/Chief resident, Department of Pediatrics, Sri Action Balaji Medical Institute

## **Honors**

2016 Investigator Award, Hyundai Hope on Wheels Young  
2014 Presentation Award, Pediatric Cancer Research Forum  
2012 Grant Award, David Yaches Foundation  
2011 Abstract Achievement Award, ASH  
2008 Award of Excellence in Research, Maimonides Medical Center  
2003 Memorial Gold Medal Award, SMS Medical College, India

## **C. Contribution to Science**

1. I am a member of the Clinical Investigations and Precision Therapeutics (CIPT) Program at the Rutgers Cancer Institute of New Jersey.

The Overall Goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to 1) translate outstanding science across the Cancer Center into early phase trials, 2) develop novel diagnostic, prevention, and therapeutic strategies; and 3) promote bidirectional translation from bench to bedside and back.

I serve as the PI on the following Clinical Trial studies at the Rutgers Cancer Institute:

-COG - ALTE2031: StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors.

-An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1).

2. Some of my contributions in the field are listed here.
  - a. Bhatla T, Dandekar S, Lu BY, Wang J, Han E, Bitterman D, Jones CL, Evensen NA, Magid M, Meyer JA, Carroll WL. Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. *J Pediatr Hematol Oncol*. 2016 Jan;38(1):e21-5. PubMed Central PMCID: PMC4681625.
  - b. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. *Blood*. 2015 Nov 5;126(19):2202-12. PubMed Central PMCID: PMC4635116.
  - c. Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. *Br J Haematol*. 2014 Oct;167(1):87-99. PubMed Central PMCID: PMC4207443.
  - d. Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. *J Pediatr Hematol Oncol*. 2014 Aug;36(6):413-8. PubMed Central PMCID: PMC4264573.